key: cord-0742520-x71cjegm
authors: Gunatilaka, Avanka B; Marco, Nicholas; Read, Graham H; Sweeney, Maggie; Regan, Greg; Tsang, Cynthia; Abdulrahman, Lobna; Ampabathina, Swetha; Spindler, Archie; Lu, Sarah S; Schink, Elena; Gatti, Richard; Ingersoll, Christina; Telesca, Donatello; Weidhaas, Joanne B
title: Viral burden and clearance in asymptomatic COVID-19 Patients
date: 2022-03-16
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac126
sha: e6d973a5090501f6a3315a2d20440e5d2ab2e2cd
doc_id: 742520
cord_uid: x71cjegm

BACKGROUND: Containing COVID-19 has been difficult, due to both the large number of asymptomatic infected individuals and the long duration of infection. To best manage these challenges requires understanding of differences between asymptomatic versus symptomatic patients and those with a longer duration of infectivity. METHODS: Individuals from Los Angeles were tested for COVID-19, and a group positive for COVID-19 chose to have follow-up testing. Associations between symptoms and demographic factors, viral burden measured by cycle threshold (CT) value, and duration of PCR positivity were analyzed. RESULTS: 18.8% of patients were positive for COVID-19. Asymptomatic COVID-19 positive patients were significantly younger that symptomatic patients (2.6 years, p<0.001). There were no differences in average CT between asymptomatic and symptomatic patients. The estimated median duration of COVID-19 PCR positivity was 23 days. Being asymptomatic throughout the course of infection was the only factor associated with a shorter course of COVID-19 PCR positivity (21 versus 28 days, p=0.002). CONCLUSIONS: We found important differences and similarities between asymptomatic and symptomatic COVID-19 positive patients, the most meaningful being a similar level of virus as measured by PCR, but a shorter duration of PCR positivity for asymptomatic patients. These findings suggest that asymptomatic patients may have more efficient clearance of virus, which may be relevant for management and screening.

In this study we sought to gain a better understanding of the differences between asymptomatic 32 and symptomatic patients, as well as identify any indicators of duration of COVID-19 PCR positivity, 33 through the study of a large cohort of COVID-19 tested individuals. 34 35

Description of the Full Cohort 37

The cohort of patients tested was collected through a group of clinics in LA county that offered 38 free testing to individuals who were either symptomatic or were believed to have had a known COVID-39 19 exposure. The cohort included 26,334 individuals tested for COVID-19 using an EUA-approved PCR 40 assay with demographic and symptom information including age, sex and ethnicity between April 9 th 41 and June 20 th , 2020. Ethnicity was recorded as either Hispanic or Non-Hispanic. Repeat testing was 42 allowed at these clinics at will, and 433 individuals had two or more A c c e p t e d M a n u s c r i p t demographic characteristics (age, sex and ethnicity) and symptomatic profile (cough, fever, 48 gastrointestinal (GI) issues). Univariate associations were assessed using a two-sample t-test for 49 continuous predictors (age) and a z-test for equal proportions for categorical predictors (sex, ethnicity, 50 symptomatic profile). A multivariable analysis for the probability of a positive test vs. symptomatic 51 profiles, adjusting for age, sex, and ethnicity, was carried out using a logistic regression model. 52

The sub-cohort of patients receiving a positive COVID-19 test were analyzed separately to assess 53 how viral load at detection relates to symptomatic profiles and basic demographic characteristics. A 54 surrogate measure of viral load was defined using CT (cycle-threshold) cycles, considered the standard 55

to measure viral levels [15] . In this study the smallest value for CT between two RT-PCR probes for 56 COVID-19 (N1 and N2) was used. CT values were related to symptomatic profiles, adjusting for 57 demographic characteristics using a linear regression model. 58

In both analyses, together with a detailed comparison of different symptoms, we also 59 considered a combined indicator of asymptomatic cases, by defining a patient to be asymptomatic if 60 they presented with no cough, fever, or GI issues. 61 reported stratifying by RT-PCR test result (positive/negative). In this descriptive univariate analysis, we 103 found that asymptomatic patients were less likely to have a positive test (4.5% difference, p<0.001). 104 Similar associations were found stratifying by type of symptoms. A positive COVID-19 test result was 105 more likely in patients reporting to have a cough, a fever or GI symptoms (p<0.001), with the largest 106 symptom differences being with cough and fever (9.45% and 8.48% higher in positive versus negative 107 patients). Patients receiving a positive COVID-19 test result where also on average 1 year younger 108 compared to negative COVID-19 test result patients (p<0.001). Positivity rates did not change 109 M a n u s c r i p t 9 significantly with gender. Finally, there were a higher proportion of Hispanic patients in the positive 110 versus the negative group (7.8% difference, p<0.001). 111

Results from a multivariable logistic regression analysis focusing on how symptomatic profiles 112 associate with the probability of a positive COVID-19 test are reported in Supplemental Table 2 . Among 113 patients of similar age, gender and ethnicity, lack of symptoms at the time of testing (being 114 asymptomatic) is associated with a decreased probability of a positive test (OR = 0.592, p<0.001). 115

Stratifying by type of symptom at the time of testing, patients experiencing cough had a meaningfully 116 higher probability of testing positive for COVID-19 (OR=1.439, p<0.001). Similar findings were found in 117 subjects experiencing fever (OR=2.129, p<0.001). GI symptoms were not found to be significantly 118 associated with the odds of a positive test. Considering demographic characteristics as potential risk 119 factors, we found that among patients with a similar symptomatic profile, only ethnicity was 120 meaningfully associated with the probability of a positive test, with non-Hispanic subjects exhibiting a 121 lower probability of positivity (OR=0.390, p<0.001). Age was also statistically associated with PCR 122 positivity (p=0.005), but its effect size is relatively small compared to the other predictors (OR=0.97 for a 123

10-year age-difference, OR=0.84 for a 60-year age difference). 124

Within the sub-cohort of patients with a positive COVID-19 test, we investigated how CT values, 127 as a surrogate measurement of viral load, associated with symptoms profiles and demographic 128 characteristics. Sample characteristics of this positive sub-cohort are summarized in Table 1 . 129

Asymptomatic patients were on average 2.6 years younger than symptomatic patients (p<0.001). Small, 130 but unremarkable differences were found between symptomatic and asymptomatic patients in terms of 131 average CT and ethnic composition. 132 Individuals were allowed to come for multiple tests at these clinics at their request, and 433 151 patients presented at least two times for testing. Using these data, we were able to evaluate the 152 percentage of patients who remained asymptomatic throughout the duration of their illness, versus who 153 were simply "presymptomatic" at their first test. We found that 51. While the exact cut-off for "infectiousness" of COVID-19 between humans will likely never be 214 determined, our findings of average CTs in the high 20s for both asymptomatic and symptomatic 215 individuals is unarguably in an infectious range. In addition, our high proportion of individuals classified 216 as "asymptomatic" in this study may be due to a limited number of symptoms recorded, which was due 217 to the timing that the data set was collected, early in the pandemic. However, our findings agree with 218 several others and are not outside of the range of asymptomatic cases that they also reported [5] . 219

Finally, our repeat testing cohort was a "convenience sample" and self-selected, versus planned, which 220 could have led to some bias. A c c e p t e d M a n u s c r i p t 20 A c c e p t e d M a n u s c r i p t 22 A c c e p t e d M a n u s c r i p t 23 

Persistence and clearance of viral RNA in 2019 novel 260 coronavirus disease rehabilitation patients

SARS-CoV-2, SARS-CoV, and 262 MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic 263 review and meta-analysis

Definition of an immunologic response 265 using the major histocompatibility complex tetramer and enzyme-linked immunospot assays

Within-Host Diversity of SARS-CoV-2 in 268

COVID-19 Patients With Variable Disease Severities

Factors associated with negative conversion of viral RNA

Viral RNA load as determined by cell culture as 273 a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

Estimating the 276 extent of asymptomatic COVID-19 and its potential for community transmission: systematic 277 review and meta-analysis

GI: TRUE 32 (7.4%)